Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) has been given an average rating of “Hold” by the thirteen research firms that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $45.43.
A number of equities research analysts recently issued reports on DCPH shares. B. Riley started coverage on Deciphera Pharmaceuticals in a research report on Monday, December 31st. They issued a “buy” rating and a $34.00 price objective on the stock. BidaskClub downgraded Deciphera Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 22nd. Zacks Investment Research downgraded Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, February 12th. Canaccord Genuity lowered their price objective on Deciphera Pharmaceuticals from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Friday, March 15th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $53.00 price objective on shares of Deciphera Pharmaceuticals in a research report on Thursday, December 20th.
Shares of DCPH stock traded down $0.44 on Monday, reaching $22.52. The company’s stock had a trading volume of 2,678 shares, compared to its average volume of 183,338. The company has a debt-to-equity ratio of 0.04, a quick ratio of 13.24 and a current ratio of 13.24. Deciphera Pharmaceuticals has a 12-month low of $18.55 and a 12-month high of $45.61. The company has a market capitalization of $876.84 million, a PE ratio of -7.99 and a beta of 3.18.
In other Deciphera Pharmaceuticals news, insider Michael Douglas Taylor sold 1,700 shares of the firm’s stock in a transaction dated Tuesday, February 5th. The stock was sold at an average price of $28.01, for a total transaction of $47,617.00. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Thomas Patrick Kelly sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, February 19th. The shares were sold at an average price of $30.00, for a total value of $45,000.00. The disclosure for this sale can be found here. Insiders have sold 193,126 shares of company stock worth $5,114,146 in the last 90 days. Company insiders own 20.61% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Great West Life Assurance Co. Can purchased a new stake in Deciphera Pharmaceuticals during the fourth quarter valued at about $50,000. Legal & General Group Plc increased its holdings in shares of Deciphera Pharmaceuticals by 55.4% in the third quarter. Legal & General Group Plc now owns 1,647 shares of the company’s stock worth $64,000 after buying an additional 587 shares during the period. MetLife Investment Advisors LLC purchased a new position in shares of Deciphera Pharmaceuticals in the third quarter worth about $235,000. Rhumbline Advisers increased its holdings in shares of Deciphera Pharmaceuticals by 53.6% in the fourth quarter. Rhumbline Advisers now owns 11,466 shares of the company’s stock worth $241,000 after buying an additional 4,000 shares during the period. Finally, Barclays PLC increased its holdings in shares of Deciphera Pharmaceuticals by 187.7% in the fourth quarter. Barclays PLC now owns 13,908 shares of the company’s stock worth $292,000 after buying an additional 9,073 shares during the period. Institutional investors and hedge funds own 57.37% of the company’s stock.
Deciphera Pharmaceuticals Company Profile
Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.
Featured Article: How Investors Can Profit from Options Trading
Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.